Branaplam
id:
branaplam-163-3231591
title:
Branaplam
text:
Branaplam is a pyridazine derivative that is being studied as an experimental drug. It was originally developed by Novartis to treat spinal muscular atrophy (SMA); since 2020 it was being developed to treat Huntington's disease but the trial ended in 2023 due to toxicity concerns. As a treatment for SMA, branaplam increases the amount of functional survival of motor neuron protein produced by the SMN2 gene through modifying its splicing pattern. It was studied since 2014 in a clinical trial in c
brand slug:
wiki
category slug:
encyclopedia
description:
Chemical compound
original url:
https://en.wikipedia.org/wiki/Branaplam
date created:
2017-03-10T13:07:14Z
date modified:
2024-08-28T11:55:24Z
main entity:
{"identifier":"Q27285985","url":"https://www.wikidata.org/entity/Q27285985"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/9/9b/Branaplam_skeletal.svg","width":512,"height":230}
fields total:
13
integrity:
16